Sionna Therapeutics (NASDAQ:SION) Shares Down 7.5% – What’s Next?

Sionna Therapeutics, Inc. (NASDAQ:SION) fell 7.5% on Tuesday . The stock traded as low as $37.76 and last traded at $37.79. 158,672 shares were traded during mid-day trading, a decline of 38% from the average session volume of 257,118 shares. The stock had previously closed at $40.85.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SION shares. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a research note on Monday. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a research report on Monday, December 1st. Jones Trading started coverage on Sionna Therapeutics in a research note on Monday, September 8th. They issued a “buy” rating and a $46.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.29.

Sionna Therapeutics Price Performance

The company has a fifty day moving average of $40.37 and a two-hundred day moving average of $29.45. The stock has a market capitalization of $1.66 billion and a P/E ratio of -7.64.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 94,583 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $44.54, for a total transaction of $4,212,726.82. Following the completion of the sale, the director owned 3,610,376 shares in the company, valued at $160,806,147.04. The trade was a 2.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Cloonan sold 99,800 shares of the stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $36.26, for a total transaction of $3,618,748.00. Following the sale, the chief executive officer directly owned 547,343 shares in the company, valued at $19,846,657.18. This trade represents a 15.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,522,064 shares of company stock valued at $56,869,839 over the last quarter. Insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

A number of large investors have recently modified their holdings of the company. Bank of America Corp DE boosted its stake in Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after purchasing an additional 529 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Sionna Therapeutics by 35.2% during the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Sionna Therapeutics during the third quarter worth approximately $30,000. Police & Firemen s Retirement System of New Jersey bought a new position in Sionna Therapeutics in the 2nd quarter worth approximately $45,000. Finally, The Manufacturers Life Insurance Company increased its position in Sionna Therapeutics by 13.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,038 shares of the company’s stock valued at $660,000 after acquiring an additional 4,489 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.